Steven W Pipe

List of Publications by Year
in descending order

188 papers	6,754 citations	66315 42 h-index	71651 76 g-index
192 all docs	192 docs citations	192 times ranked	4871 citing authors

#	Article	IF	Citations
1	WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia, 2020, 26, 1-158.	1.0	915
2	Antioxidants reduce endoplasmic reticulum stress and improve protein secretion. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 18525-18530.	3.3	593
3	Bleeding due to disruption of a cargo-specific ER-to-Golgi transport complex. Nature Genetics, 2003, 34, 220-225.	9.4	282
4	Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. Lancet Haematology,the, 2019, 6, e295-e305.	2.2	252
5	Bioengineering of coagulation factor VIII for improved secretion. Blood, 2004, 103, 3412-3419.	0.6	193
6	Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A. Blood, 2016, 128, 2007-2016.	0.6	165
7	Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A. New England Journal of Medicine, 2022, 386, 1013-1025.	13.9	157
8	Differential Interaction of Coagulation Factor VIII and Factor V with Protein Chaperones Calnexin and Calreticulin. Journal of Biological Chemistry, 1998, 273, 8537-8544.	1.6	137
9	Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies. Blood, 2021, 137, 2231-2242.	0.6	133
10	Characterization of a genetically engineered inactivation-resistant coagulation factor VIIIa. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 11851-11856.	3.3	122
11	New therapies for hemophilia. Blood, 2019, 133, 389-398.	0.6	120
12	Mannose-dependent Endoplasmic Reticulum (ER)-Golgi Intermediate Compartment-53-mediated ER to Golgi Trafficking of Coagulation Factors V and VIII. Journal of Biological Chemistry, 1999, 274, 32539-32542.	1.6	117
13	Four Hydrophobic Amino Acids of the Factor VIII C2 Domain Are Constituents of Both the Membrane-binding and von Willebrand Factor-binding Motifs. Journal of Biological Chemistry, 2002, 277, 6374-6381.	1.6	103
14	Recombinant clotting factors. Thrombosis and Haemostasis, 2008, 99, 840-850.	1.8	96
15	Mutagenesis of a Potential Immunoglobulin-binding Protein-binding Site Enhances Secretion of Coagulation Factor VIII. Journal of Biological Chemistry, 1997, 272, 24121-24124.	1.6	94
16	Hemophilia A mutations associated with 1-stage/2-stage activity discrepancy disrupt protein-protein interactions within the triplicated A domains of thrombin-activated factor VIIIa. Blood, 2001, 97, 685-691.	0.6	93
17	Optimal management of patent ductus arteriosus in the neonate weighing less than 800 g. Journal of Pediatric Surgery, 1993, 28, 1137-1139.	0.8	89
18	Functional roles of the factor VIII B domain. Haemophilia, 2009, 15, 1187-1196.	1.0	86

#	Article	IF	Citations
19	The promise and challenges of bioengineered recombinant clotting factors. Journal of Thrombosis and Haemostasis, 2005, 3, 1692-1701.	1.9	85
20	Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B. Blood Advances, 2019, 3, 3241-3247.	2.5	85
21	Lactadherin blocks thrombosis and hemostasis inÂvivo: correlation with platelet phosphatidylserine exposure. Journal of Thrombosis and Haemostasis, 2008, 6, 1167-1174.	1.9	82
22	The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing. Lancet, The, 2021, 397, 630-640.	6.3	71
23	Neonatal thromboembolic emergencies. Seminars in Fetal and Neonatal Medicine, 2006, 11, 198-206.	1.1	67
24	A von Willebrand factor fragment containing the Dâ€²D3 domains is sufficient to stabilize coagulation factor VIII in mice. Blood, 2014, 124, 445-452.	0.6	60
25	Interlaboratory agreement in the monitoring of unfractionated heparin using the anti-factorÂXa-correlated activated partial thromboplastin time. Journal of Thrombosis and Haemostasis, 2009, 7, 80-86.	1.9	58
26	Association of peak factor <scp>VIII</scp> levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokineticâ€guided prophylaxis. Haemophilia, 2016, 22, 514-520.	1.0	58
27	LMAN1 is a molecular chaperone for the secretion of coagulation factor VIII1. Journal of Thrombosis and Haemostasis, 2003, 1, 2360-2367.	1.9	57
28	The role of telemedicine in the delivery of health care in the COVIDâ€19 pandemic. Haemophilia, 2020, 26, e230-e231.	1.0	57
29	Neonatal purpura fulminans in association with factor V R506Q mutation. Journal of Pediatrics, 1996, 128, 706-709.	0.9	55
30	Clinical Considerations for Capsid Choice in the Development of Liver-Targeted AAV-Based Gene Transfer. Molecular Therapy - Methods and Clinical Development, 2019, 15, 170-178.	1.8	55
31	Gene therapy, bioengineered clotting factors and novel technologies for hemophilia treatment. Journal of Thrombosis and Haemostasis, 2007, 5, 901-906.	1.9	54
32	In vivo efficacy of platelet-delivered, high specific activity factor VIII variants. Blood, 2010, 116, 6114-6122.	0.6	54
33	Regulation of Factor VIII Expression and Activity by von Willebrand Factor. Thrombosis and Haemostasis, 1999, 82, 201-208.	1.8	52
34	Prophylactic therapy with Fibrogammin^{Â®} P is associated with a decreased incidence of bleeding episodes: a retrospective study. Haemophilia, 2010, 16, 316-321.	1.0	52
35	Characterization of central venous catheterâ€“associated deep venous thrombosis in infants. Journal of Pediatric Surgery, 2012, 47, 1159-1166.	0.8	49
36	Reduction of Anti-FVIII Inhibitor Titers in Hemophilic Mice Infused with Syngeneic Apoptotic Cells Expressing a Human FVIII Transgene.. Blood, 2005, 106, 216-216.	0.6	49

#	Article	IF	Citations
37	Factor VIII C2 Domain Missense Mutations Exhibit Defective Trafficking of Biologically Functional Proteins. Journal of Biological Chemistry, 1996, 271, 25671-25676.	1.6	47
38	The future of recombinant coagulation factors. Journal of Thrombosis and Haemostasis, 2003, 1, 922-930.	1.9	47
39	A membrane-interactive surface on the factor VIII C1 domain cooperates with the C2 domain for cofactor function. Blood, 2011, 117, 3181-3189.	0.6	46
40	Novel therapeutics for hemophilia and other bleeding disorders. Blood, 2018, 132, 23-30.	0.6	46
41	Correction of Murine Hemophilia A and Immunological Differences of Factor VIII Variants Delivered by Helper-dependent Adenoviral Vectors. Molecular Therapy, 2007, 15, 2080-2087.	3.7	45
42	The hope and reality of longâ€acting hemophilia products. American Journal of Hematology, 2012, 87, S33-9.	2.0	45
43	Post-thrombotic Syndrome in Children: A Single Center Experience. Journal of Pediatric Hematology/Oncology, 2008, 30, 261-266.	0.3	44
44	Hemophilia A Mutations within the Factor VIII A2-A3 Subunit Interface Destabilize Factor VIIIa and Cause One-stage/ Two-stage Activity Discrepancy. Thrombosis and Haemostasis, 2002, 88, 781-787.	1.8	43
45	Hemophilia: New Protein Therapeutics. Hematology American Society of Hematology Education Program, 2010, 2010, 203-209.	0.9	42
46	Mortality in congenital hemophilia AÂâ€“Âa systematic literature review. Journal of Thrombosis and Haemostasis, 2021, 19, 6-20.	1.9	41
47	Discussing investigational AAV gene therapy with hemophilia patients: A guide. Blood Reviews, 2021, 47, 100759.	2.8	40
48	The Enhancing Effects of the Light Chain on Heavy Chain Secretion in Split Delivery of Factor VIII Gene. Molecular Therapy, 2007, 15, 1856-1862.	3.7	39
49	Recombinant factor VIII Fc fusion protein for immune tolerance induction in patients with severe haemophilia A withÂinhibitorsâ€”A retrospective analysis. Haemophilia, 2018, 24, 245-252.	1.0	39
50	Platelet binding sites for factor VIII in relation to fibrin and phosphatidylserine. Blood, 2015, 126, 1237-1244.	0.6	37
51	Recognizing the need for personalization of haemophilia patientâ€reported outcomes in the prophylaxis era. Haemophilia, 2016, 22, 825-832.	1.0	36
52	Extending the pharmacokinetic half-life of coagulation factors by fusion to recombinant albumin. Thrombosis and Haemostasis, 2013, 110, 931-939.	1.8	35
53	New therapies for hemophilia. Hematology American Society of Hematology Education Program, 2016, 2016, 650-656.	0.9	33
54	Expression of Factor VIII in Recombinant and Transgenic Systems. Blood Cells, Molecules, and Diseases, 2002, 28, 234-248.	0.6	32

#	Article	IF	Citations
55	Biosynthetic origin and functional significance of murine platelet factor V. Blood, 2003, 102, 2851-2855.	0.6	32
56	Conservative mutations in the C2 domains of factor VIII and factor V alter phospholipid binding and cofactor activity. Blood, 2012, 120, 1923-1932.	0.6	32
57	Gene therapy for hemophilia. Pediatric Blood and Cancer, 2018, 65, e26865.	0.8	30
58	Healthcare resource utilization among haemophilia A patients in the United States. Haemophilia, 2012, 18, 332-338.	1.0	29
59	Biological mechanisms underlying interâ€individual variation in factor VIII clearance in haemophilia. Haemophilia, 2020, 26, 575-583.	1.0	29
60	New high-technology products for the treatment of haemophilia. Haemophilia, 2004, 10, 55-63.	1.0	28
61	Factor VIII therapy for hemophilia A: current and future issues. Expert Review of Hematology, 2014, 7, 373-385.	1.0	27
62	Establishment of embryonic stem cells secreting human factorÂVIII for cellâ€based treatment of hemophiliaÂA. Journal of Thrombosis and Haemostasis, 2008, 6, 1352-1359.	1.9	26
63	Most factor VIII B domain missense mutations are unlikely to be causative mutations for severe hemophilia A: implications for genotyping. Journal of Thrombosis and Haemostasis, 2011, 9, 1183-1190.	1.9	26
64	Efficacy of emicizumab in a pediatric patient with type 3 von Willebrand disease and alloantibodies. Blood Advances, 2019, 3, 2748-2750.	2.5	26
65	Core data set on safety, efficacy, and durability of hemophilia gene therapy for a global registry: Communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2020, 18, 3074-3077.	1.9	24
66	Coagulation Factors with Improved Properties for Hemophilia Gene Therapy. Seminars in Thrombosis and Hemostasis, 2004, 30, 227-237.	1.5	23
67	Treatment of Thrombosis With Fondaparinux (Arixtra) in a Patient With End-stage Renal Disease Receiving Hemodialysis Therapy. Journal of Pediatric Hematology/Oncology, 2007, 29, 581-584.	0.3	23
68	Bleeding Disorders. Pediatrics in Review, 2008, 29, 121-130.	0.2	22
69	Bioengineering of coagulation factor VIII for efficient expression through elimination of a dispensable disulfide loop. Journal of Thrombosis and Haemostasis, 2012, 10, 107-115.	1.9	22
70	Emicizumab for hemophilia A with factor VIII inhibitors. Expert Review of Hematology, 2018, 11, 835-846.	1.0	22
71	Hemophilia A gene therapy: current and next-generation approaches. Expert Opinion on Biological Therapy, 2022, 22, 1099-1115.	1.4	22
72	Delivering on the promise of gene therapy for haemophilia. Haemophilia, 2021, 27, 114-121.	1.0	21

#	Article	IF	Citations
73	The effect of emicizumab prophylaxis on longâ€term, selfâ€reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies. Haemophilia, 2021, 27, 854-865.	1.0	21
74	Combined factor V and factor VIII deficiency in a Thai patient: a case report of genotype and phenotype characteristics. Haemophilia, 2005, 11, 280-284.	1.0	20
75	The U.S. Thrombosis and Hemostasis Centers pilot sites program. Journal of Thrombosis and Thrombolysis, 2007, 23, 1-7.	1.0	20
76	Experience with a third generation recombinant factor VIII concentrate (Advate^{Â®}) for immune tolerance induction in patients with haemophilia A. Haemophilia, 2009, 15, 718-726.	1.0	20
77	Management of Neonatal Aortic Arch Thrombosis With Low-molecular Weight Heparin. Journal of Pediatric Hematology/Oncology, 2009, 31, 516-521.	0.3	19
78	Modeling to Predict Factor VIII Levels Associated with Zero Bleeds in Patients with Severe Hemophilia A Initiated on Tertiary Prophylaxis. Thrombosis and Haemostasis, 2020, 120, 728-736.	1.8	19
79	Establishing the appropriate primary endpoint in haemophilia gene therapy pivotal studies. Haemophilia, 2017, 23, 643-644.	1.0	18
80	Suppression of FVIII Inhibitor Formation in Hemophilic Mice by Delivery of Transgene Modified Apoptotic Fibroblasts. Molecular Therapy, 2010, 18, 214-222.	3.7	17
81	Onâ€demand treatment of bleeds in haemophilia patients with inhibitors: strategies for securing and maintaining predictable efficacy with recombinant activated factor VII. Haemophilia, 2012, 18, 255-262.	1.0	16
82	Switching clotting factor concentrates: considerations in estimating the risk of immunogenicity. Haemophilia, 2014, 20, 200-206.	1.0	15
83	The evolution of recombinant factor replacement for hemophilia. Transfusion and Apheresis Science, 2019, 58, 596-600.	0.5	15
84	Antihemophilic factor (recombinant) plasma/albumin-free method for the management and prevention of bleeding episodes in patients with hemophilia A. Biologics: Targets and Therapy, 2009, 3, 117.	3.0	15
85	Inferior vena cavectomy for nonexcisable Wilms' tumor thrombus. Journal of Pediatric Surgery, 2001, 36, 526-529.	0.8	14
86	Consideration in Hemophilia Therapy Selection. Seminars in Hematology, 2006, 43, S23-S27.	1.8	14
87	Functional factorÂVIII made with von Willebrand factor at high levels in transgenic milk. Journal of Thrombosis and Haemostasis, 2011, 9, 2235-2242.	1.9	14
88	Innovations in coagulation: improved options for treatment of hemophilia A and B. Thrombosis Research, 2013, 131, S1.	0.8	14
89	The Role of Platelets and Îµ-Aminocaproic Acid in Arthrogryposis, Renal Dysfunction, and Cholestasis (ARC) Syndrome Associated Hemorrhage. Pediatric Blood and Cancer, 2016, 63, 561-563.	0.8	14
90	HIF1-alpha Regulates Acinar Cell Function and Response to Injury in Mouse Pancreas. Gastroenterology, 2018, 154, 1630-1634.e3.	0.6	14

#	Article	IF	Citations
91	Hemophilia gene therapy knowledge and perceptions: Results of an international survey. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 644-651.	1.0	14
92	Management of COVIDâ€19â€associated coagulopathy in persons with haemophilia. Haemophilia, 2021, 27, 41-48.	1.0	14
93	Application of a hemophilia mortality framework to the Emicizumab Global Safety Database. Journal of Thrombosis and Haemostasis, 2021, 19, 32-41.	1.9	14
94	Evolution of haemophilia integrated care in the era of gene therapy: Treatment centreâ€™s readiness in United States and EU. Haemophilia, 2021, 27, 511-514.	1.0	13
95	Neonatal Sinovenous Thrombosis Associated With Homozygous Thermolabile Methylenetetrahydrofolate Reductase in Both Mother and Infant. Journal of Perinatology, 2002, 22, 175-178.	0.9	12
96	Fitusiran, an Investigational siRNA Therapeutic Targeting Antithrombin for the Treatment of Hemophilia: First Results from a Phase 3 Study to Evaluate Efficacy and Safety in People with Hemophilia a or B without Inhibitors (ATLAS-A/B). Blood, 2021, 138, LBA-3-LBA-3.	0.6	12
97	Visions in haemophilia care. Thrombosis Research, 2009, 124, S2-S5.	0.8	11
98	Fitusiran, an RNAi Therapeutic Targeting Antithrombin to Restore Hemostatic Balance in Patients with Hemophilia a or B with or without Inhibitors: Management of Acute Bleeding Events. Blood, 2019, 134, 1138-1138.	0.6	11
99	Hemophilia A mutations within the factor VIII A2-A3 subunit interface destabilize factor VIIIa and cause one-stage/two-stage activity discrepancy. Thrombosis and Haemostasis, 2002, 88, 781-7.	1.8	11
100	Gene therapy: Practical aspects of implementation. Haemophilia, 2022, 28, 44-52.	1.0	11
101	Molecular defects in coagulation Factor VIII and their impact on Factor VIII function. Vox Sanguinis, 2002, 83, 89-96.	0.7	10
102	Go long! A touchdown for factor VIII?. Blood, 2010, 116, 153-154.	0.6	10
103	Coagulation status after therapeutic plasma exchange using citrate in kidney transplant recipients. Transfusion, 2016, 56, 3073-3080.	0.8	10
104	Bioengineered molecules for the management of haemophilia: Promise and remaining challenges. Haemophilia, 2018, 24, 68-75.	1.0	10
105	First-in-Human Gene Therapy Study of AAVhu37 Capsid Vector Technology in Severe Hemophilia A - BAY 2599023 has Broad Patient Eligibility and Stable and Sustained Long-Term Expression of FVIII. Blood, 2020, 136, 44-45.	0.6	10
106	Interlaboratory Precision in the Monitoring of Unfractionated Heparin Using the Anti-Factor Xa-Correlated Activated Partial Thromboplastin Time. Blood, 2008, 112, 435-435.	0.6	10
107	What is the role of an extended half-life product in immune tolerance induction in a patient with severe hemophilia A and high-titer inhibitors?. Hematology American Society of Hematology Education Program, 2016, 2016, 648-649.	0.9	9
108	Argatroban monitoring: aPTT versus chromogenic assay. American Journal of Hematology, 2016, 91, E303-4.	2.0	9

#	Article	IF	Citations
109	Emicizumab prophylaxis to facilitate anticoagulant therapy for management of intraâ€atrial thrombosis in severe haemophilia with an inhibitor. Haemophilia, 2019, 25, e203-e205.	1.0	9
110	Vaccination against COVIDâ€19: Rationale, modalities and precautions for patients with haemophilia and other inherited bleeding disorders. Haemophilia, 2021, 27, 515-518.	1.0	9
111	Executive summary of the NHLBI State of the Science (SOS) Workshop: Overview and next steps in generating a national blueprint for future research on factor VIII inhibitors. Haemophilia, 2019, 25, 610-615.	1.0	8
112	Patient preference for emicizumab versus prior factor therapy in people with haemophilia A: Results from the HAVEN 3 and HAVEN 4 studies. Haemophilia, 2021, 27, e772-e775.	1.0	8
113	Perinatal hematology. Seminars in Fetal and Neonatal Medicine, 2016, 21, 1.	1.1	7
114	Establishment of a framework for assessing mortality in persons with congenital hemophilia A and its application to an adverse event reporting database. Journal of Thrombosis and Haemostasis, 2021, 19, 21-31.	1.9	7
115	First-in-human Gene Therapy Study of AAVhu37 Capsid Vector Technology in Severe Hemophilia A. Blood, 2019, 134, 4630-4630.	0.6	7
116	Pain and functional disability amongst adults with moderate and severe haemophilia from the Irish personalised approach to the treatment of haemophilia (iPATH) study. European Journal of Haematology, 2022, 108, 518-527.	1.1	7
117	Defibrotide Therapy for SARS-CoV-2 ARDS. Chest, 2022, 162, 346-355.	0.4	7
118	Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12) Tj ETQq0 0 0 rgBT /Overlock 10	1.0	7
119	Origins and organization of the NHLBI State of the Science Workshop: Generating a national blueprint for future research on factor VIII inhibitors. Haemophilia, 2019, 25, 575-580.	1.0	6
120	Gene editing in hemophilia: a â€œCRISPRâ€•choice?. Blood, 2019, 133, 2733-2734.	0.6	6
121	Realâ€world data of immune tolerance induction using recombinant factor VIII Fc fusion protein in patients with severe haemophilia A with inhibitors at high risk for immune tolerance induction failure: A followâ€up retrospective analysis. Haemophilia, 2021, 27, 19-25.	1.0	6
122	Bleeding Disorders. Pediatrics in Review, 2008, 29, 121-130.	0.2	6
123	The physician's role in selecting a factor replacement therapy. Haemophilia, 2006, 12, 21-25.	1.0	5
124	Safety and efficacy of recombinant activated coagulation factor VII in congenital hemophilia with inhibitors in the home treatment setting: A review of clinical studies and registries. American Journal of Hematology, 2017, 92, 940-945.	2.0	5
125	Preference for Emicizumab over Prior Factor Treatments: Results from the HAVEN 3 and HAVEN 4 Studies. Blood, 2018, 132, 1187-1187.	0.6	5
126	The Secretion Efficiency of Factor VIII Can Be Regulated by the Size and Oligosaccharide Content of the B Domain.. Blood, 2005, 106, 687-687.	0.6	5

#	Article	IF	Citations
127	Incremental Improvement in Bioengineering of Coagulation Factor VIII for Efficient Expression: Elimination of a Dispensable Disulfide Loop Enhances Secretion. Blood, 2008, 112, 3073-3073.	0.6	5
128	Estimating the risk of thrombotic events in people with congenital hemophilia A using US claims data. Journal of Comparative Effectiveness Research, 2021, 10, 1323-1336.	0.6	5
129	Safety and Efficacy of Recombinant Factor VIIa (rFVIIa) in Congenital Hemophilia with Inhibitors (CHwI) in the Home Treatment Setting: Systematic Review of Clinical Studies and Registries. Blood, 2015, 126, 2302-2302.	0.6	5
130	First-in-Human Dose-Finding Study of AAVhu37 Vector-Based Gene Therapy: BAY 2599023 Has Stable and Sustained Expression of FVIII over 2 Years. Blood, 2021, 138, 3971-3971.	0.6	5
131	A Cornucopia of Therapies under Study for Hemophilia. Molecular Therapy, 2017, 25, 2429-2430.	3.7	4
132	Antiâ€factor IIa (FIIa) heparin assay for patients on direct factor Xa (FXa) inhibitors. Journal of Thrombosis and Haemostasis, 2020, 18, 1653-1660.	1.9	4
133	Not in the genotype: can unexplained hemophilia A result from â€œmicro(RNA) managementâ€?. Transfusion, 2020, 60, 227-228.	0.8	4
134	Phage display broadly identifies inhibitorâ€reactive regions in von Willebrand factor. Journal of Thrombosis and Haemostasis, 2021, 19, 2702-2709.	1.9	4
135	One Year Data from a Phase 2b Trial of AMT-061 (AAV5-Padua hFIX variant), an Enhanced Vector for Gene Transfer in Adults with Severe or Moderate-Severe Hemophilia B. Blood, 2019, 134, 3348-3348.	0.6	4
136	Reduction of Inhibitory Anti-FVIII Antibody Titer by Using a B Domain Variant FVIII/N6 cDNA for Nonviral Gene Therapy in Hemophilia a Mice. Blood, 2008, 112, 3537-3537.	0.6	4
137	Modeling Minimally-Effective FVIII Trough Levels in Hemophilia a Patients on PK-Guided Prophylaxis. Blood, 2014, 124, 689-689.	0.6	4
138	Understanding Ectopically Expressed Factor VIII (F8) In Megakaryocytes: Implications for Optimum Platelet-Delivered F8 Activity for Gene Therapy. Blood, 2010, 116, 2205-2205.	0.6	4
139	A chamber of hope for hemophilia. Nature Biotechnology, 2000, 18, 264-265.	9.4	3
140	Outcomes of mentored, grantâ€funded fellowship training in haemostasis /thrombosis: findings from a nested caseâ€“control survey study. Haemophilia, 2012, 18, 326-331.	1.0	3
141	Elucidation of the Roles of Individual Asparagine-Linked Glycans Outside of the B Domain on Factor VIII Secretion. Blood, 2011, 118, 2238-2238.	0.6	3
142	Modelling FVIII Levels for Prediction of Zero Spontaneous-Joint Bleeding in a Cohort of Severe Hemophilia a Subjects with Target Joints Initiated on Tertiary Prophylaxis. Blood, 2016, 128, 2576-2576.	0.6	3
143	Long-Term Durability, Safety and Efficacy of Fitusiran Prophylaxis in People with Hemophilia a or B, with or without Inhibitors - Results from the Phase II Study. Blood, 2020, 136, 3-4.	0.6	3
144	Longitudinal Assessment of Thrombin Generation in Patients with Hemophilia Receiving Fitusiran Prophylaxis: Phase II Study Results. Blood, 2020, 136, 36-37.	0.6	3

#	Article	IF	Citations
145	Tricuspid Valve Thrombus and Pulmonary Embolus in an Infant with Homozygous Thermolabile Methylenetetrahydrofolate Reductase and Heterozygous Prothrombin G20210A Variant. Journal of Perinatology, 2003, 23, 513-515.	0.9	2
146	Bleeding Data across Baseline FIX Expression Levels in People with Hemophilia B: An Analysis Using the 'Factor Expression Study'. Blood, 2021, 138, 592-592.	0.6	2
147	Management of Hemophilia in the Midst of Emerging Pathogens: A Societal Perspective. Seminars in Hematology, 2006, 43, S1-S3.	1.8	1
148	Antihemophilic factor (recombinant) plasma/albumin-free method for the management and prevention of bleeding episodes in patients with hemophilia A. Biologics: Targets and Therapy, 0, , 117.	3.0	1
149	How we approach: Training pediatric coagulationists. Pediatric Blood and Cancer, 2019, 66, e27982.	0.8	1
150	Acquired von Willebrand Syndrome in an Infant With Coarctation of the Aorta and Williams Syndrome. World Journal for Pediatric & Congenital Heart Surgery, 2020, 11, NP91-NP93.	0.3	1
151	Diagnosis and management of von Willebrand disease: A communityâ€wide effort to deliver evidenceâ€based clinical practice guidelines. Haemophilia, 2021, 27, 181-183.	1.0	1
152	Regulated Phosphatidylserine Exposure on Platelets Mediates Fibrin Formation in Hemostasis and Thrombosis.. Blood, 2005, 106, 1645-1645.	0.6	1
153	Prophylactic Therapy with Fibrogammin Is Associated with a Decreased Incidence of Bleeding Episodes: A Retrospective Case Control Study.. Blood, 2006, 108, 1014-1014.	0.6	1
154	Risk for Post Thrombotic Syndrome (PTS) Development in Children with Extremity Deep Venous Thrombosis (DVT): Results of the US Centers for Disease Control and Prevention (CDC) Pediatric Thrombosis and Hemostasis Centers.. Blood, 2009, 114, 4000-4000.	0.6	1
155	Real-World Data of Immune Tolerance Induction Using rFVIIIFc in Subjects With Severe Hemophilia A With Inhibitors at High Risk for ITI Failure. Blood, 2018, 132, 2500-2500.	0.6	1
156	Eptacog Beta Efficacy in Children and Adolescents with Hemophilia A or B and Inhibitors: Subset Analysis Suggests Improved Caregiver Capacity to Assess Bleeding Episode Resolution with Subject Age. Blood, 2021, 138, 3195-3195.	0.6	1
157	Challenges and opportunities when transitioning from in vivo gene replacement to in vivo CRISPR/Cas9 therapies â€“ a spotlight on hemophilia. Expert Opinion on Biological Therapy, 2022, 22, 1091-1098.	1.4	1
158	339. FIV Lentiviral Vector Gene Transfer for Hemophilia A. Molecular Therapy, 2006, 13, S129.	3.7	0
159	Reduction of inhibitor titres by infusion of FVIII gene transduced tolerogenic dendritic cells in haemophilic mice. Haemophilia, 2009, 15, 634-634.	1.0	0
160	Factors for life: advances in the treatment of congenital and coagulopathic bleeding disorders. Thrombosis Research, 2011, 128, S1.	0.8	0
161	Comparison of Activated Protein C Resistance With Factor V Leiden Testing by Molecular Assay. American Journal of Clinical Pathology, 2019, 152, S5-S5.	0.4	0
162	New treatment paradigm for hemophilia poses challenges for legacy bioassays. Journal of Thrombosis and Haemostasis, 2019, 17, 1446-1448.	1.9	0

#	Article	IF	Citations
163	His2315/Gln2316 of the Factor VIII C2 Domain Interact with Phospholipid Membranes and Influence Activity of the Factor Xase Complex.. Blood, 2004, 104, 1727-1727.	0.6	0
164	Induction of Tolerance to FVIII in Hemophilic Mice by Delivery of Apoptotic Syngeneic Fibroblasts Expressing a FVIII Transgene.. Blood, 2006, 108, 768-768.	0.6	0
165	An Essential Role of the Factor VIII Light Chain in Facilitating Heavy Chain Secretion.. Blood, 2006, 108, 4034-4034.	0.6	0
166	Hemostasis and Thrombosis Centers Pilot Sites Registry: Thrombophilia Evaluation in Children.. Blood, 2006, 108, 3298-3298.	0.6	0
167	Prevention of Early Arteriovenous Fistula Failure Due to Thromosis: Experience with Primary Thromboprophylaxis.. Blood, 2006, 108, 885-885.	0.6	0
168	Inactivation-Resistant Recombinant Factor VIII Exhibits Superior Thrombin Generation Capacity in Comparison to Wild-Type and B Domain-Deleted Factor VIII.. Blood, 2006, 108, 1604-1604.	0.6	0
169	Antioxidants Improve Factor VIII Secretion in the Liver by Preventing Oxidative Stress, Activation of the Unfolded Protein Response, and Apoptosis.. Blood, 2006, 108, 197-197.	0.6	0
170	The Mutations SER2117â†'LEU, and TRP/TRP2063/64â†'MET/PHE in the Hydrophobic Spikes of the Factor V C2 Domain Lead to Tenacious Phospholipid Binding and Suggest a Mechanism through Which Phosphatidylserine Activates the Prothrombinase Complex.. Blood, 2007, 110, 2703-2703.	0.6	0
171	An Expanded Post-Thrombosis Sequelae Assessment Scale in Children.. Blood, 2007, 110, 3196-3196.	0.6	0
172	Most Factor VIII B Domain Missense Mutations Are Unlikely to Be Causative Mutations for Hemophilia A: Implications for Factor VIII Genetic Analysis. Blood, 2008, 112, 513-513.	0.6	0
173	Use of rFVIIa in Individuals with Congenital Hemophilia B Complicated by Alloantibody Inhibitors to Factor IX: Analysis of Data Capture from the Hemophilia and Thrombosis Research Society (HTRS) Registry (2004â€"2008). Blood, 2008, 112, 4521-4521.	0.6	0
174	Strategies for Securing and Maintaining Predictable Efficacy with Recombinant Activated Factor VII in On-Demand Treatment of Haemophilia Patients with Inhibitors.. Blood, 2009, 114, 4443-4443.	0.6	0
175	Strategies to Enhance the Efficacy of Platelet-Derived Factor (F) VIII: Studies with Inactivation Resistant FVIII (IR8) and Canine FVIII in Hemophilia A Mice.. Blood, 2009, 114, 3496-3496.	0.6	0
176	Membrane-Interactive Amino Acids in the Factor VIII C1 Domain Are Cooperative with C2 Domain Epitopes for Membrane Binding and Cofactor Function.. Blood, 2009, 114, 848-848.	0.6	0
177	The CDC Hemostasis and Thrombosis Centers (HTC) Pilot Sites: Data From the Pediatric Registry.. Blood, 2009, 114, 2990-2990.	0.6	0
178	Asparagine-Linked Glycosylation at the NH2-Terminus Does Not Influence Secretion or Function of Coagulation Factors V and VIII. Blood, 2010, 116, 2220-2220.	0.6	0
179	Endoplasmic Reticulum to Mitochondria Ca2+ Signaling Inhibits Factor VIII Secretion and Mediates Oxidative Stress and Apoptosis Upon Factor VIII Expression. Blood, 2010, 116, 2212-2212.	0.6	0
180	Conservative Mutations in the Membrane-Binding Motif of Factor V C2 Domain to Residues of Pseudonaja Textilis Venom Factor V Confer Phosphatidylserine-Independent Activity. Blood, 2011, 118, 2243-2243.	0.6	0

#	Article	IF	Citations
181	Thrombin-Stimulated Platelets Have Functional Binding Sites For Factor VIIIa That Are Distinct From Phosphatidylserine. Blood, 2013, 122, 3582-3582.	0.6	0
182	Improving Hematologist/Oncologist Knowledge and Confidence in Managing Hemophilia through Online Educational Interventions. Blood, 2015, 126, 5593-5593.	0.6	0
183	Congenital Bleeding Disorders. , 2019, , 95-110.		0
184	The Irish Personalized Approach to the Treatment of Haemophilia (iPATH) - Determinants of Inter-Individual Variation in FVIII Pharmacokinetics. Blood, 2018, 132, 1190-1190.	0.6	0
185	Relationship between Endogenous, Transgene FVIII Expression and Bleeding Events Following Valoctocogene Roxaparvovec Gene Transfer for Severe Hemophilia A: A Post-Hoc Analysis of the GENEr8-1 Phase 3 Trial. Blood, 2021, 138, 3972-3972.	0.6	0
186	Defibrotide Therapy for Sars CoV2 Acute Respiratory Distress Syndrome. Blood, 2021, 138, 3237-3237.	0.6	0
187	In Vitro Evaluation of Thrombin Generation of Eptacog Beta (Factor VIIa, Recombinant) and Emicizumab in Congenital Hemophilia Î˚ Plasma with and without Inhibitors. Blood, 2020, 136, 41-42.	0.6	0
188	Inhibit Clinical Trials Platform to Prevent and Eradicate Inhibitors: Feasibility Survey of Current Prophylaxis and Immune Tolerance Practices. Blood, 2020, 136, 14-15.	0.6	0